Ποια είναι η τιμή για Applied Molecular Transport Inc. (AMTI)

Η τιμή για Applied Molecular Transport Inc. (AMTI) είναι $0.263

Ποια είναι η κεφαλαιοποίηση αγοράς για Applied Molecular Transport Inc. (AMTI)

Η κεφαλαιοποίηση αγοράς για Applied Molecular Transport Inc. (AMTI) είναι $9.26M

Applied Molecular Transport Inc. (AMTI) Κέρδη

Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.

Έτος	Κέρδη	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

Κέρδη

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	Κέρδη	Διαφορά Κερδών	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Εταιρεία

Κέρδη

Διαφορά Κερδών

Χώρα